Company
Damora Therapeutics, Inc. (DMRA)
Standardized SEC financial data for Damora Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001800315 · NASDAQ · Pharmaceutical Preparations.
Return on equity
-87.3%
Free cash flow
-$6.9M
Current ratio
12.98×
EPS (diluted)
$3.98
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| R&D expense | $24.6M | $38.5M | $48.2M | $23.8M | $6.4M | $26.9M |
| SG&A expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $163.8M | $62.6M | $32.8M | $21.5M | $14.2M | $257.6M |
| Total current assets |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$38.2M | -$52.3M | -$42.9M | -$36.9M | -$18.6M | -$6.7M |
| Capital expenditures |
Get DMRA data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/DMRA/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/DMRA/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"